Persephone : Duration of Trastuzumab with Chemotherapy in patients with early breast cancer : Six months versus twelve
- Registry ID
- EUCTR2006-007018-39
- Source registry
- EUCTR
- Status
- GB - no longer in EU/EEA
- Phase
- PHASE3
- Sponsor
- Cambridge Hospitals NHS Foundation Trust and Cambridge University
- Start date
- 2007-05-10
- Last update
- 2026-08-16
Conditions
- HER2 positive early breast cancer
Summary
Primary objective: A phase III, randomised trial comparing 6 months trastuzumab treatment with 12 months, in patients with Her 2 positive early breast cancer, in terms of disease-free and overall survival.
Primary endpoint
Disease-free survival non-inferiority (equivalence) of 6 months trastuzumab to 12 months in early breast cancer.
Locations
View on source registry